PATENT CLAIM ANALYSIS

Application Number: 16132064
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["424", "093210"]

Abstract:
Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Claim (Index 36):
A pharmaceutical composition comprising an anti-tumor effective amount of a population of human T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises at least one extracellular antigen binding domain comprising a CD19 antigen binding domain comprising the amino acid sequence of SEQ ID NO. 2, 4, 6, 8, 10, 12, 14, or 16, at least one linker domain, at least one transmembrane domain, at least one intracellular signaling domain, and wherein the T cells are T cells of a human having a cancer.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 97.0
- Lexical Diversity: 1.53659
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15866222', '16050754', '15934770', '15511973', '15767076']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.776211880741319
- 35 USC 102 Novelty (BERT): 0.6572667853066391
- Combined Prediction Score: 0.764317371197851
- Mean Citation Score: 583.192748
- Max Citation Score: 654.763
- Similarity Product: 606.482997317493

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test